AnaptysBio Inc (ANAB) Receives Average Recommendation of “Buy” from Analysts
Shares of AnaptysBio Inc (NASDAQ:ANAB) have been assigned an average recommendation of “Buy” from the nine research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $84.78.
A number of equities analysts have commented on ANAB shares. Zacks Investment Research raised AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 price objective on the stock in a research note on Friday, November 10th. SunTrust Banks began coverage on AnaptysBio in a research note on Wednesday, November 15th. They set a “buy” rating and a $115.00 price target on the stock. Credit Suisse Group upped their price target on AnaptysBio from $34.00 to $38.00 and gave the company an “outperform” rating in a research note on Friday, August 25th. Royal Bank Of Canada upped their price target on AnaptysBio from $40.00 to $79.00 and gave the company an “outperform” rating in a research note on Tuesday, October 10th. Finally, JMP Securities upped their price target on AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a research note on Tuesday, October 10th.
Several institutional investors and hedge funds have recently modified their holdings of the company. Evercore Wealth Management LLC acquired a new position in AnaptysBio in the third quarter valued at about $100,000. Legal & General Group Plc lifted its stake in AnaptysBio by 160.8% in the third quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 1,951 shares during the period. Bank of America Corp DE acquired a new position in AnaptysBio in the first quarter valued at about $123,000. DAFNA Capital Management LLC lifted its stake in AnaptysBio by 22.2% in the second quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 1,000 shares during the period. Finally, New York State Common Retirement Fund acquired a new position in AnaptysBio in the second quarter valued at about $168,000. 75.48% of the stock is currently owned by institutional investors and hedge funds.
AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.02. analysts anticipate that AnaptysBio will post -1.72 EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/07/anaptysbio-inc-anab-receives-average-recommendation-of-buy-from-analysts.html.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc and related companies with MarketBeat.com's FREE daily email newsletter.